Invesaro

Stocks PVLA Earnings

Earnings

Palvella Therapeutics, Inc. (PVLA) earnings

Quarterly results of Palvella Therapeutics, Inc. as filed with the SEC: revenue, net income and earnings per share for each of the last 8 quarters, the latest results release and when the next one is expected.

Free, no password. An email when PVLA files with the SEC.

Next earnings date

Palvella Therapeutics, Inc. is expected to report around February 23, 2027. That is an estimate from its filing rhythm (a year after the same report last year), not a date the company has announced.

Latest quarter: Q3 FY2026

In Q3 FY2026 (ended September 30, 2026) Palvella Therapeutics, Inc. reported revenue of - and a net loss of $24.6M.

Diluted earnings per share were -$1.70.

Filed with the SEC on November 5, 2026.

Net income by quarter
Q4 24: -$4M -$4M Q4 24Q1 25: -$8.2M -$8.2M Q1 25Q2 25: -$9.5M -$9.5M Q2 25Q3 25: -$11.3M -$11.3M Q3 25Q4 25: -$12.7M -$12.7M Q4 25Q1 26: -$15.8M -$15.8M Q1 26Q2 26: -$21.9M -$21.9M Q2 26Q3 26: -$24.6M -$24.6M Q3 26

Quarter by quarter

QuarterEndedRevenuevs year agoNet incomeEPS
Q3 FY2026September 30, 2026---$24.6M-$1.70
Q2 FY2026June 30, 2026---$21.9M-$1.52
Q1 FY2026March 31, 2026---$15.8M-$1.20
Q4 FY2025December 31, 2025---$12.7M-
Q3 FY2025September 30, 2025---$11.3M-$1.03
Q2 FY2025June 30, 2025---$9.5M-$0.86
Q1 FY2025March 31, 2025---$8.2M-$0.74
Q4 FY2024December 31, 2024---$4M-

Fourth quarters are the fiscal year minus the first three, as most companies report no separate Q4 figures.

Results filings

When is Palvella Therapeutics, Inc.'s next earnings date?

Palvella Therapeutics, Inc. is expected to report around February 23, 2027. That is an estimate from its filing rhythm (a year after the same report last year), not a date the company has announced.

Get an email when PVLA reports

Follow PVLA and we email you its next results the day they are filed, with the numbers explained.

Free, no password. An email when PVLA files with the SEC.

Source: quarterly figures Palvella Therapeutics, Inc. tags in its 10-Q and 10-K filings (SEC EDGAR XBRL). Not investment advice.

Everything about Palvella Therapeutics, Inc.